.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Delving into Updates in Metastatic Hormone-Sensitive Prostate Cancer

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss updates in the metastatic hormone-sensistive prostate cancer realm.

EP. 1: The Evolution of Treatment in Metastatic Hormone-Sensitive Prostate Cancer

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.

EP. 2: Data From an Age-Related Subgroup Analysis of the ARASENS Trial in mHSPC

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.

EP. 3: Outcomes by Disease Volume: A Subgroup Analysis of the ARANOTE Trial in mHSPC

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.

EP. 4: Findings From a Real-World Analysis of ARPIs in Nonmetastatic CRPC

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.

EP. 5: Ongoing Research to Watch in Prostate Cancer in 2025 and Beyond

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.

EP. 6: Key Prostate Cancer Updates to Emerge From ASCO GU 2025

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.